等效法在伏安法测量中的应用

本文提出了在伏安法测量中，消除电表内阻对实验结果影响的一种新方法     

复合结构丝中的电流密度分布和巨磁阻抗效应

提出了由中间为高电导率的非铁磁性金属丝外面包裹一层铁磁材料组成的复合结构丝的电流 密度分布和巨磁阻抗(GMI)效应模型，并对Cu/FeCoNi复合丝进行了数值模拟. 结果表明：在 相同的磁性材料几何尺寸和磁特性时，Cu/FeCoNi复合丝铁磁层内的电流随频率的升高比匀 质FeCoNi铁磁丝内的电流更趋于表面分布，而且开始出现趋肤效应时对应的频率明显降低. 当在比较低的频率下就可以观察到明显的MI变化时，复合结构丝中的电阻和电抗变化主要是 由趋肤效应引起，趋肤效应仍然是引起复合结构材料(包括多层薄膜结构) 关键词： 电流密度 巨磁阻抗效应 趋肤效应     

A 3D-BPP approach for optimising stowage plans and terminal productivity

This paper addresses the problem of determining stowage plans for containers in a ship, that is the so-called master bay plan problem (MBPP).     

EAST�ŵ����ֵģ�⼰����������

用TSC程序模拟了EAST装置等离子体放电的全过程。模拟中考虑了自举电流，并加入了离子回旋共振加热ICRH和快波电流驱动FWCD，得到了中心电子温度4.5keV、中心离子温度3.8keV、中心电子密度1.2×1020m–3的D形截面的等离子体。根据模拟结果对EAST装置进行了伏秒数分析，并研究了不同等离子体电流上升时间、有效电荷数Zeff对放电的影响。     

程控电流示波计时电位法

使用计算机产生极化电流具有纯度高，稳定性好和波形形状种类多等优点。研究了极化电流的频率，波形和相角对示波图的影响。对Ｃｄ＾２＋的测定的线性范围为２×１０＾－５～２×１０＾－４ｍｏｌ／Ｌ，相关系数为０．９９７，该方法可且希望用于分析测试和动力学方面的研究。     

VA族元素对阳极铅(Ⅱ)氧化物膜半导体性质的影响(Ⅱ)

用光电化学电流法研究了铅、铅砷、铅锑和铅铋合金在4．5mol·L－1H2SO4溶液（22℃）中，以0．9V（vs．Hg／Hg2SO4）极化7h而形成的阳极膜中的氧化铅的半导体性质，合金添加剂砷、锑和铋对t－PbO（四方氧化铝）和o-PbO（斜方氧化铝）的禁带宽度没有影响，从量子效率和电位的关系可求Pb，Pb－lat％As（at％表示原子百分比，全文同），Pb-lat％Sb和Sb－lat％Bi上膜中t－Pbo的施主密度（ND）分别为9．3×1015，1．0×1016，3．1×1016和1．3×1017cm-3，平带位分别为-0．20，－0．22，－0．28和-0．08V（vs．Hg／Hg2SO4）．比较VA元素砷、锑和铋对上述膜中t－Pbo的ND（从而自由电子密度）和膜中t－Pbo的生长速率的影响，可认为法添加剂砷、锑和铋对阳极膜中t-Pbo的作用符合Hauffe规则．     

三线性直接分解法分析高维灰色体系

对于由多个两维测量数据组成的三维阵，本文提出一种新三线性直接分解方法。采用高维ＰＣＡ分解，从三维阵中直接提取抽象光谱和抽象浓度，再结合ＱＺ算法，唯一地确定混合物中各组分光谱的浓度。该方法可以排除其它未知组分的干扰，适用于高维灰色体系定性定量分析和多点校准。用模拟数据讨论了光谱分离度对该方法的影响，应用于混合维生素Ｂ１、Ｂ２和Ｂ６的荧光分析，求得的光谱和浓度与实验值吻合很好。     

Accuracy and long-term reproducibility of lead isotopic measurements by multiple-collector inductively coupled plasma mass spectrometry using an external method for correction of mass discrimination

The precision of isotopic measurements of Pb by thermal ionization mass spectrometry (TIMS) is limited by the fact that this element does not possess an invariant isotope ratio that can be used for the correction of mass fractionation by internal normalization. Multiple-collector inductively coupled plasma mass spectrometry (MC-ICPMS) can overcome this limitation, because with plasma ionization, elements with overlapping mass ranges are thought to display identical mass discrimination. With respect to Pb, this can be exploited by the addition of Tl to the sample solutions; the mass discrimination factor obtained for Tl can then be used for the correction of the measured Pb isotope ratios. In this article we present the results of a detailed study that investigates the accuracy and precision of such an external correction technique for mass discrimination based upon the results of multiple analyses of a mixed standard solution of NIST SRM-981 Pb and SRM-997 Tl. Our data indicate that normalization of the Pb isotope ratios to the certified isotopic composition of SRM-997 Tl produces Pb isotopic results that are significantly lower than recently published reference values by TIMS. This systematic offset can be eliminated by renormalization of the Pb data to a different Tl isotopic composition to obtain an empirically determined mass discrimination factor for Pb that generates accurate results. It is furthermore shown that a linear law is least suited for the correction of mass discrimination, whereas a power or exponential law function provide significantly more accurate and precise results. In detail, it appears that a power law may provide the most appropriate correction procedure, because the corrected Pb isotope ratios display less residual correlations with mass discrimination compared to the exponentially corrected data. Using an exponential or power law correction our results, obtained over a period of over seven months, display a precision (2σ) of better than 60 parts per million (ppm) for ²⁰⁸Pb/²⁰⁶Pb and ²⁰⁷Pb/²⁰⁶Pb and of better than 350 ppm for ²⁰⁶Pb/²⁰⁴Pb, ²⁰⁷Pb/²⁰⁴Pb/²⁰⁴Pb, and ²⁰⁸Pb/²⁰⁴Pb. This represents a significant improvement compared to conventional TIMS techniques and demonstrates the potential of MC-ICPMS for routine, high-precision measurements of Pb isotopic compositions.     

三维有序大孔杂化材料SiW11O39^8——SiO2和γ—SiW10O36^8——SiO2的制备与表征

通过溶胶 -凝胶和聚苯乙烯模板等方法制备了含缺位 Keggin阴离子 Si W1 1 O8- 3 9和 γ-Si W1 0 O8- 3 6的三维有序大孔杂化氧化硅复合材料 ,并通过紫外漫反射光谱 ( UV/ DRS)、傅里叶变换红外光谱 ( FTIR)、固体核磁共振波谱 ( MAS NMR)等手段对其结构进行了表征 .结果表明 ,杂化材料中的 Keggin阴离子仍保留其基本骨架结构 ,但其与氧化硅基体之间存在化学作用 .杂化材料的孔道结构用扫描和透射电子显微镜 ( SEM和TEM)进行表征 ,其平均孔径为 ( 335± 5 0 ) nm.对杂化材料孔壁的微孔性通过氮气吸附进行了测定 .此类材料对水溶液中羟基丁二酸的降解反应具有活性 ,光催化过程中未发现 Keggin阴离子自载体中脱落的现象 .     

Metabolomic-based investigation of Yinlan alleviating hyperlipidemia by inhibiting blood stasis and phlegm turbidity through the PXR-CYP3A4-ABCB1-FXR pathway

Yinlan lipid regulatory capsule (YL) is a composite traditional Chinese medicine (TCM) new drug to alleviate hyperlipidemia, while its therapeutic mechanism in vivo was not clarified with nontargeted metabolomics investigation. An animal model was established in rats fed a high-fat diet, and their body weights, body mass index (BMI) and blood cholesterol levels were measured. Serum, liver and kidney tissue samples were also extracted for PXR-CYP3A4-ABCB1-FXR signaling pathway research using PCR and UHPLC–MS. The obtained plasma samples were analyzed by UHPLC-Q-TOF-MS metabolomic investigation, which revealed PXR-CYP3A4-related metabolites and changes induced by YL. Finally, the key metabolites were chosen as index components, and their levels in the serum, liver, small intestine and bile were used for simultaneous UHPLC–MS-MS determination. The results indicated that YL was effective in rebalancing blood TG and TC levels (compared to controls). With respect to the PXR-CYP3A4-ABCB1 pathway, as a result of YL’s effect, gene expression or activity of the two targets decreased significantly in both the liver and kidney. The same trend was observed in the serum samples mentioned above. Metabolomics screening and data revealed that 44 metabolites can be regarded as biomarkers related to hyperlipidemia, fatty acids synthesis, and body energy consumption, as well as synthesis, transportation and exertion of cholesterol. YL’s treatment focused on 26 of them, primarily bile acids, indicating that the antihyperlipidemic effect of this drug lies in its inhibitory activity of cholesterol metabolism. Subsequent analysis of those in vivo components revealed that significant increases (compared to the model group) occurred in the blood, liver, small intestine and bile in groups that received medium and high doses of YL (while the low dose was relatively unchanged). Those target components exhibit a close relationship with PXR and/or CYP3A4. The use of YL repressed PXR expression and subsequently decreased CYP3A4 activity. As a result, synthesis of related bile acids increased, while cholesterol levels decreased, consequently leading to the attenuation of hyperlipidemia. This study comprehensively investigated the antihyperlipidemia mechanism of YL based on its repression of PXR-CYP3A4 activity and related metabolite yield, establishing an accurate method for evaluating the therapeutic effect of YL.